| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE U | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 3 | NIH | 2/13/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = -$99,823 ) |
| | 2024 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE U | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 3 | NIH | 4/3/2024 | $0 |
| | 2024 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE U | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 4 | NIH | 10/1/2023 | -$99,823 |
| | 2024 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE U | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 001 | 4 | NIH | 2/1/2024 | $0 |
| | 2024 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE U | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 002 | 4 | NIH | 9/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 3 | NIH | 6/30/2023 | $0 |
| | 2023 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA162629 | Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | 000 | 3 | NIH | 5/26/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $897,757 ) |
| | 2022 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 3 | NIH | 3/24/2022 | $826,939 |
| | 2022 | 2022 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 001 | 4 | NIH | 8/23/2022 | $70,818 |
| | 2022 | 2021 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 3 | NIH | 10/29/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $141,660 ) |
| | 2021 | 2021 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 3 | NIH | 8/30/2021 | $141,660 |
| | 2021 | 2020 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 001 | 2 | NIH | 9/7/2021 | $0 |
| | 2021 | 2020 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 002 | 2 | NIH | 9/8/2021 | $0 |
| | 2021 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA162629 | Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | 000 | 3 | NIH | 8/9/2021 | $0 |
| | 2021 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 1 | NIH | 3/19/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,062,115 ) |
| | 2020 | 2020 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 001 | 2 | NIH | 9/1/2020 | $1,062,115 |
| | 2020 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA162629 | Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | 000 | 3 | NIH | 9/11/2020 | $0 |
| | 2020 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 1 | NIH | 3/2/2020 | $0 |
| | 2020 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 2 | NIH | 8/26/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 2 | NIH | 9/10/2019 | $0 |
| | 2019 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 1 | NIH | 8/28/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,094,089 ) |
| | 2018 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA162629 | Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | 000 | 3 | NIH | 8/29/2018 | $833,374 |
| | 2018 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA224718 | Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer | 000 | 1 | NIH | 8/31/2018 | $159,365 |
| | 2018 | 2018 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 2 | NIH | 8/23/2018 | $1,101,350 |
| | 2018 | 2017 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R43CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 1 | NIH | 8/7/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,307,315 ) |
| | 2017 | 2017 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R43CA210817 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer | 000 | 1 | NIH | 3/2/2017 | $152,589 |
| | 2017 | 2017 | A&G PHARMACEUTICAL, INC. | 9130 RED BRANCH RD STE X | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA162629 | Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies | 000 | 2 | NIH | 9/15/2017 | $1,154,726 |
|
| Issue Date FY: 2014 ( Subtotal = $69,040 ) |
| | 2014 | 2014 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R03NS085693 | Granulin specific monoclonal antibodies to investigate their expression and role | 000 | 2 | NIH | 8/20/2014 | $69,040 |
| | 2014 | 2011 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045 | HOWARD | USA | R43CA153800 | Serum GP88 biomarker as a surrogate marker for disease progression in breast canc | 000 | 1 | NIH | 6/9/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $69,737 ) |
| | 2013 | 2013 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R03NS085693 | Granulin specific monoclonal antibodies to investigate their expression and role | 000 | 1 | NIH | 9/2/2013 | $69,737 |
| | 2013 | 2011 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045 | HOWARD | USA | R43CA153800 | Serum GP88 biomarker as a surrogate marker for disease progression in breast canc | 000 | 1 | NIH | 5/3/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $193,879 ) |
| | 2012 | 2012 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R43CA162629 | TARGETED THERAPY FOR NON SMALL CELL LUNG CARCINOMA: IN VIVO FEASIBILITY STUDIES | 000 | 1 | NIH | 8/14/2012 | $193,879 |
| | 2012 | 2011 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045 | HOWARD | USA | R43CA153800 | Serum GP88 biomarker as a surrogate marker for disease progression in breast canc | 000 | 1 | NIH | 4/23/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $691,398 ) |
| | 2011 | 2011 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA124179 | NOVEL TARGETED THERAPY FOR BREAST CANCER | 000 | 3 | NIH | 6/20/2011 | $578,078 |
| | 2011 | 2011 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R43CA153800 | Serum GP88 biomarker as a surrogate marker for disease progression in breast canc | 000 | 1 | NIH | 9/26/2011 | $113,320 |
|
| Issue Date FY: 2010 ( Subtotal = $575,793 ) |
| | 2010 | 2010 | A&G PHARMACEUTICAL INC | 9130 RED BRANCH ROAD | COLUMBIA | MD | 21045-2006 | HOWARD | USA | R44CA124179 | NOVEL TARGETED THERAPY FOR BREAST CANCER | 000 | 2 | NIH | 7/16/2010 | $575,793 |
|
|
